1. Home
  2. FLNG vs MESO Comparison

FLNG vs MESO Comparison

Compare FLNG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FLEX LNG Ltd.

FLNG

FLEX LNG Ltd.

HOLD

Current Price

$30.88

Market Cap

1.7B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.12

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNG
MESO
Founded
2006
2004
Country
Bermuda
Australia
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2019
2005

Fundamental Metrics

Financial Performance
Metric
FLNG
MESO
Price
$30.88
$15.12
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
★ $23.00
N/A
AVG Volume (30 Days)
★ 398.5K
179.7K
Earning Date
05-13-2026
02-26-2026
Dividend Yield
★ 9.40%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$2.14
$30.65
P/E Ratio
$19.72
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.00
$13.05
52 Week High
$33.40
$21.50

Technical Indicators

Market Signals
Indicator
FLNG
MESO
Relative Strength Index (RSI) 43.63 44.31
Support Level $30.38 $14.18
Resistance Level $31.17 $16.06
Average True Range (ATR) 0.71 0.42
MACD -0.15 -0.05
Stochastic Oscillator 7.06 36.29

Price Performance

Historical Comparison
FLNG
MESO

About FLNG FLEX LNG Ltd.

Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: